|

Registration benefits include:
|
|
Access to CME/CE programs and certification
|
|
Free subscription to Biologic Bulletin newsletter
|
|
Reminders of new CME/CE activities
|
REGISTER NOW
|
|

|
 |
|
 |
 |
| |
PsoriasisTx.com is a free educational Web site designed to provide dermatologists, dermatology residents and fellows, dermatology nurses, and other dermatology professionals with the latest information about biologic therapies used to treat patients with moderate to severe psoriasis.
A variety of resources are available regarding treatments for psoriasis, including:
- General information about biologic therapies for psoriasis
- A wide selection of continuing medical education (CME) and continuing education (CE) programs accredited by Curatio CME Institute and other accrediting organizations. CME/CE opportunities include newsletters, webcasts, and more (free registration required)
- Exclusive Expert Practice articles from renowned faculty, including Alan Menter, MD; Mark G. Lebwohl, MD; Gerald G. Krueger, MD;
- An extensive meetings section, featuring detailed reports from recent dermatology meetings and a comprehensive listing of upcoming psoriasis-related meetings and symposia with links to event Web sites
- Access to selected journal articles on topics relating to the treatment of psoriasis
- A free subscription to our exclusive Biologic Bulletin newsletter (free registration required)
- And much more, including the Ask the Expert forum where our expert panel addresses your most difficult psoriasis cases
Thank you for visiting PsoriasisTx.com. We hope you find the information on new psoriasis treatment options useful in your efforts to keep apace with ongoing developments in biologic therapy and the ways biologic agents are changing treatment paradigms.
CLOSING THE GAP
 |
How confident are you in your knowledge of the mechanisms of immune system modulation associated with the pathophysiology of psoriasis?
|
|
WHAT'S NEW
 |
Addressing Cardiovascular Comorbidities in Psoriasis PatientsCME-Certified Biologic Bulletin Edited by Bruce Strober, MD, PhD and Melodie Young, MSN, RN, A/GNP-C
|
 |
Managing the Psoriasis Patient With Concomitant Disease (CME) A Clinically Challenging Case Presented by Jeffrey J. Crowley, MD and Melodie Young, MSN, RN, A/GNP-C
|
 |
A Practical Guide to the Management of Psoriatic Arthritis: Defining the Role of Dermatology Professionals An interview with Kenneth B. Gordon, MD
|
NEW! - Clinically Challenging Cases - Expert Insights
CME SPOTLIGHT
 |

|
CME-Certified Biologic Bulletin Edited by Bruce Strober, MD, PhD and Melodie Young, MSN, RN, A/GNP-C
The systemic inflammatory nature of psoriasis and its association with cardiovascular comorbidities are important considerations for the management of patients with psoriasis. Moreover, the recognition that younger patients with more severe disease are at increased risk for poor cardiovascular outcomes warrants early detection of patients who are most at risk for cardiovascular disease. This Biologic Bulletin examines the risk for cardiovascular disease in patients with psoriasis, the mechanisms that contribute to cardiovascular comorbidites, and the effect that psoriasis treatment has on cardiovascular outcomes.
|
|
EXPERT PRACTICE HIGHLIGHT
 |

|
Strategies for Managing Complex Psoriasis Cases
CME-Certified Expert Practice Article
An interview with Neil J. Korman, MD
To accurately measure treatment efficacy, clinical trials of psoriasis therapies enroll homogeneous patient populations. Outside of clinical trials, psoriasis patients exhibit considerable variability in their overall health status. Psoriasis patients who have comorbid conditions, such as HIV or multiple sclerosis, represent a treatment challenge for dermatologists. In this Expert Practice, Dr. Neil Korman from the Murdough Family Center for Psoriasis at University Hospitals Case Medical Center discusses how to approach the treatment of psoriasis patients with concomitant diseases or preexisting medical conditions. Dr. Korman also addresses another treatment challenge, the management of patients who have recalcitrant psoriasis. Treatment strategies for patients who do not respond satisfactorily to anti–tumor necrosis factor (TNF) agents will also be addressed.
|
READ MORE |
|
|
 |


|
|